Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Will Celgene Corporation (CELG) Help You Retire Rich? – Johnson & Johnson (JNJ), AbbVie Inc (ABBV)

Page 1 of 2

Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won’t just fall into your lap. In this series, I look at 10 measures to show what makes a great retirement-oriented stock.

Celgene Corporation (NASDAQ:CELG) is a highly successful biotech company, standing out from hundreds of smaller peers with its large stable of highly successful drugs and therapies. But competition in the health-care space never goes away. How is Celgene standing up to its rivals? Let’s revisit how Celgene does on our 10-point scale.

The right stocks for retirees
With decades to go before you need to tap your investments, you can take greater risks, weighing the chance of big losses against the potential for mind-blowing returns. But as retirement approaches, you no longer have the luxury of waiting out a downturn.

Sure, you still want good returns, but you also need to manage your risk and protect yourself against bear markets, which can maul your finances at the worst possible time. The right stocks combine both of these elements in a single investment.

When scrutinizing a stock, retirees should look for:

Size. Most retirees would rather not take a flyer on unproven businesses. Bigger companies may lack their smaller counterparts’ growth potential, but they do offer greater security.
Consistency. While many investors look for fast-growing companies, conservative investors want to see steady, consistent gains in revenue, free cash flow, and other key metrics. Slow growth won’t make headlines, but it will help prevent the kind of ugly surprises that suddenly torpedo a stock’s share price.
Stock stability. Conservative retirement investors prefer investments that move less dramatically than typical stocks, and they particularly want to avoid big losses. These investments will give up some gains during bull markets, but they won’t fall as far or as fast during bear markets. Beta measures volatility, but we also want a track record of solid performance as well.
Valuation. No one can afford to pay too much for a stock, even if its prospects are good. Using normalized earnings multiples helps smooth out one-time effects, giving you a longer-term context.
Dividends. Most of all, retirees look for stocks that can provide income through dividends. Retirees want healthy payouts now and consistent dividend growth over time — as long as it doesn’t jeopardize the company’s financial health.

With those factors in mind, let’s take a closer look at Celgene.

Factor What We Want to See Actual Pass or Fail?
Size Market cap > $10 billion $47.1 billion Pass
Consistency Revenue growth > 0% in at least four of five past years 5 years Pass
Free cash flow growth > 0% in at least four of past five years 4 years Pass
Stock stability Beta < 0.9 0.64 Pass
Worst loss in past five years no greater than 20% 0.7%* Pass
Valuation Normalized P/E < 18 39.81 Fail
Dividends Current yield > 2% 0% Fail
5-year dividend growth > 10% 0% Fail
Streak of dividend increases >= 10 years NM NM
Payout ratio < 75% NM NM
Total score 5 out of 8

Source: S&P Capital IQ. NM = not meaningful; Celgene doesn’t pay a dividend. Total score = number of passes. * This figure represents a gain; Celgene’s stock has not declined in any calendar year in the past five years.

Since we looked at Celgene last year, the company has kept its five-point score. Failing to pay dividends is the kiss of death on our scale, but the stock has produced an impressive total return, gaining 50% over the past year.

Page 1 of 2
Loading Comments...